We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

the Effect Between Platelet Reactivation and Antiplatelet Drugs

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2015 by quan li, Beijing Anzhen Hospital.
Recruitment status was:  Active, not recruiting
ClinicalTrials.gov Identifier:
First Posted: July 23, 2014
Last Update Posted: July 22, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
quan li, Beijing Anzhen Hospital
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes. Compared with clopidogrel, Ticagrelor is more powerful antiplatelet drug. However, because of increased bleeding and dyspnea risk, both loading double dose and following second dose time had potential risk and inconvenient in routine clinical work, especially in elective PCI of comparable stable patients in Chinese. The benefit and risk should be balanced in such patients. The investigators supposed loading single dose and followed by second routine time dose was superior to clopidogrel and safer than ticagrelor previously prescribed.

Drug Effect Disorder Platelet Procoagulant Activity Deficiency

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.

Resource links provided by NLM:

Further study details as provided by quan li, Beijing Anzhen Hospital:

Primary Outcome Measures:
  • Platelet reactivity [ Time Frame: 1 year ]
    LTA and TEG used to measure the effect of Platelet reactivity

Biospecimen Retention:   Samples Without DNA
Platelet reactivity

Estimated Enrollment: 74
Study Start Date: May 2014
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
Ticagrelor with a dose of 90mg followed by 90 mg twice per day .

Detailed Description:

All admission patients were divided into two groups, the first group were prescribed loading dose (180 mg) ticagrelor, the second group were prescribed with 90 mg ticagrelor. We measured both platelet activity and platelet reactivity using the LTA at baseline, pre-operation and post-operation. All bleeding or dyspnea events were recorded in hospital period.

Primary endpoints: platelet activity, platelet reactivity using the LTA and safety events were recorded in hospital period.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Inclusion Criteria:

coronary artery disease, percutaneous coronary intervention

Exclusion Criteria:

high risk bleeding patient, allergic to the drugs

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02198053

Anzhen Hospital
Beijing, China, 100029
Sponsors and Collaborators
Beijing Anzhen Hospital
Study Director: LI QUAN, doctor Beijing Anzhen Hospital, Capital Medical University
  More Information

Responsible Party: quan li, associate chief physician, Beijing Anzhen Hospital
ClinicalTrials.gov Identifier: NCT02198053     History of Changes
Other Study ID Numbers: azliquan
First Submitted: July 21, 2014
First Posted: July 23, 2014
Last Update Posted: July 22, 2015
Last Verified: July 2015

Additional relevant MeSH terms:
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs